Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Non Operating Income (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Other Non Operating Income data on record, last reported at $436000.0 in Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 5.83% year-over-year to $436000.0; the TTM value through Dec 2025 reached $2.1 million, up 898.51%, while the annual FY2025 figure was $2.1 million, 898.51% up from the prior year.
  • Other Non Operating Income reached $436000.0 in Q4 2025 per LCTX's latest filing, up from $219000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $1.7 million in Q2 2025 and bottomed at -$2.7 million in Q4 2022.
  • Average Other Non Operating Income over 5 years is -$240875.0, with a median of -$184500.0 recorded in 2022.
  • Peak YoY movement for Other Non Operating Income: tumbled 539.53% in 2024, then soared 543.92% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$1.7 million in 2021, then crashed by 59.13% to -$2.7 million in 2022, then surged by 130.88% to $826000.0 in 2023, then crashed by 43.95% to $463000.0 in 2024, then dropped by 5.83% to $436000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $436000.0 in Q4 2025, $219000.0 in Q3 2025, and $1.7 million in Q2 2025.